<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01778179</url>
  </required_header>
  <id_info>
    <org_study_id>2012-03</org_study_id>
    <nct_id>NCT01778179</nct_id>
  </id_info>
  <brief_title>A Fixed Triple Combination Cream for Solar Lentigines Associated to Cryotherapy</brief_title>
  <official_title>Safety and Efficacy of a Triple Combination Cream as Adjuvant Treatment of Solar Lentigines With Cryotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brazilan Center for Studies in Dermatology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brazilan Center for Studies in Dermatology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate safety and efficacy of Tri-Luma® cream as an adjunctive treatment to cryotherapy
      when used in the pre- and post-procedure phases for the treatment of solar lentigines on the
      back of the hands and in the prevention of post-inflammatory hyperpigmentation after
      cryotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate safety and efficacy of Tri-Luma® cream as an adjunctive treatment to cryotherapy
      when used in the pre- and post-procedure phases for the treatment of solar lentigines on the
      back of the hands and in the prevention of post-inflammatory hyperpigmentation after
      cryotherapy.

      The study has 13 weeks for each subject. Five visits will take place: at Baseline, week 2, 5,
      9 and 13 after the cryotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Solar lentigines count at each visit</measure>
    <time_frame>up to 13 weeks</time_frame>
    <description>Solar lentigines count at each visit, up to 13 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of Post-inflammatory hyperpigmentation</measure>
    <time_frame>up to 13 weeks</time_frame>
    <description>scale of 4 points for post-inflammatory hyperpigmentation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Solar Lentigines</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects (group 1) will be treated daily for their solar lentigines with the investigational drug (Tri-Luma® cream) for 2 weeks.Then, at week 2, all the subjects will have the solar lentigines treated by cryotherapy (CRY-AC3® device).
Post-procedure phase (From week 2 up to Week 13 - Visit ) - Topical antibiotic treatment phase (from week 2 up to Week 5 - visit 2 up to visit 3): At week 2, all the subjects will start to apply a topical antibiotic (Neomycin/Nebacetin® ointment) for the next 3 weeks.
- Tri-Luma® cream treatment phase (from week 5 up to week 13 - visit 3 up to visit 5): The investigational drug (Tri-Luma® cream) will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects (group 2) will be treated daily for their solar lentigines only with sumscreen for 2 weeks.Then, at week 2, all the subjects will have the solar lentigines will be treated by cryotherapy (CRY-AC3® device).
Post-procedure phase (From week 2 up to Week 13 - Visit )
- Topical antibiotic treatment phase (from week 2 up to Week 5 - visit 2 up to visit 3): At week 2, all the subjects will start to apply a topical antibiotic (Neomycin/Nebacetin® ointment) for the next 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tri-luma</intervention_name>
    <description>Pre-procedure phase (From Baseline up to Week 2)treated daily for their solar lentigines with the investigational drug (Tri-Luma® cream) for 2 weeks.
Post-procedure phase (From week 2 up to Week 13 - Visit )
- Tri-Luma® cream treatment phase (from week 5 up to week 13 - visit 3 up to visit 5):The investigational drug (Tri-Luma® cream) will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH.</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryotherapy (CRY-AC3® device)</intervention_name>
    <description>Procedure performed at week 2.</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject agreement to provide written informed consent and the willingness and ability
             to comply with all aspects of the protocol;

          -  Female and male subjects;

          -  Phototype II to IV;

          -  Subjects aged between 40 and 65 years;

          -  Subjects presenting at least 5 lesions of solar lentiges at the back hands with al
             least 3mm of diameter

          -  History of post-inflammatory hyperpigmentation on body or face

          -  Medical history and physical examination which, based on the investigator's opinion,
             do not prevent the subject from taking part in the study or from making use of the
             products under investigation;

          -  Subjects of childbearing age should present a negative urine pregnancy test at
             baseline and should be using a highly effective contraceptive method during all study;

          -  Availability of the subject throughout the study;

          -  Subject agreeing not to undergo other cosmetic or dermatological procedures during the
             participation in the study;

          -  Subjects with sufficient schooling and knowledge to enable them to cooperate to the
             degree required by the protocol.

        Exclusion Criteria:

          -  Pregnant women or women intending to become pregnant in the following 5 months after
             screening;

          -  Lactation period;

          -  Subjects participating in other clinical trials;

          -  Any prior cosmetic procedures, including fillers, or scars that may interfere with the
             study results;

          -  Subjects with neoplastic, muscular or neurological diseases;

          -  Subjects with inflammation or active infection in the area to be studied;

          -  Subjects with a history of adverse effects, such as sensitivity to the components of
             any of the study drug formula,

          -  Subjects with a history of non-adherence to medical treatment or showing unwillingness
             to adhere to the study protocol;

          -  Any condition that, in the opinion of the investigator, can compromise the evaluation
             of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Doris Hexsel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brazilian Center for Studies in Dermatology</affiliation>
  </overall_official>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2013</study_first_submitted>
  <study_first_submitted_qc>January 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2013</study_first_posted>
  <last_update_submitted>July 19, 2016</last_update_submitted>
  <last_update_submitted_qc>July 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brazilan Center for Studies in Dermatology</investigator_affiliation>
    <investigator_full_name>Doris Hexsel</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Lentigines</keyword>
  <keyword>Cryotherapy</keyword>
  <keyword>hyperpigmentation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lentigo</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

